CDKN2A and chronic gastritis: In addition, chronic gastritis, intestinal metaplasia, gastric adenoma, and gastric cancer show an increasing frequency of p16/cyclin-dependent kinase inhibitor 2A (CDKN2A) methylation [22–24].